Home/Filings/4/0001209191-17-049451
4//SEC Filing

Soffer Gad 4

Accession 0001209191-17-049451

CIK 0001604464other

Filed

Aug 16, 8:00 PM ET

Accepted

Aug 17, 5:37 PM ET

Size

11.8 KB

Accession

0001209191-17-049451

Insider Transaction Report

Form 4
Period: 2017-08-15
Soffer Gad
Chief Operating Officer
Transactions
  • Sale

    Common Stock

    2017-08-15$15.00/sh7,000$105,000257,409 total
  • Sale

    Common Stock

    2017-08-16$14.53/sh2,464$35,802259,090 total
  • Exercise/Conversion

    Common Stock

    2017-08-15+4,145261,554 total
  • Exercise/Conversion

    Restricted Stock Units

    2017-08-154,1456,910 total
    Common Stock (4,145 underlying)
Footnotes (7)
  • [F1]Transaction pursuant to Rule 10b5-1 Plan adopted September 26, 2016.
  • [F2]Shares issued upon settlement of vested restricted stock units ("RSUs").
  • [F3]Shares sold to cover tax liability from settlement of RSUs.
  • [F4]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.30 to $14.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F5]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement.
  • [F6]The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date.
  • [F7]The earlier of (i) January 10, 2021 or (ii) the recipient's termination date.

Issuer

Atara Biotherapeutics, Inc.

CIK 0001604464

Entity typeother

Related Parties

1
  • filerCIK 0001612090

Filing Metadata

Form type
4
Filed
Aug 16, 8:00 PM ET
Accepted
Aug 17, 5:37 PM ET
Size
11.8 KB